Tranexamic Acid Dosing for Epistaxis

Topical Application (Preferred Route for Epistaxis)

The American Academy of Otolaryngology-Head and Neck Surgery recommends topical application of tranexamic acid 500 mg (5 mL of the injectable formulation) directly to the bleeding site on cotton pledgets or dental rolls, which is more effective than traditional nasal packing and stops bleeding within 10 minutes in the majority of patients 1
The American Academy of Otolaryngology-Head and Neck Surgery guidelines acknowledge that topical TXA has shown higher rates of acute bleeding control and earlier discharge compared to anterior nasal packing, though they note the evidence is of moderate quality and call for additional study 1

IV tranexamic acid is NOT indicated for epistaxis management, as the FDA-approved IV indication is specifically for hemophilia patients undergoing tooth extraction, with a dose of 10 mg/kg, and the IV dosing regimen used in trauma is designed for massive hemorrhage and systemic fibrinolysis, not localized nasal bleeding 2

Topical application of tranexamic acid avoids the systemic thromboembolic risks associated with IV administration, according to the American Academy of Otolaryngology-Head and Neck Surgery 1

The lysine analogues like TXA show no increased risk of arterial or venous thrombotic events in over 8,000 patients, according to the Critical Care journal 3, 4

Soaking gauze with tranexamic acid is a practice for dental extractions in liver transplant candidates with coagulopathy, particularly relevant for patients with INR values <2.50 and platelet counts >30 × 10⁹/L, as mentioned in the Journal of Hepatology 5

TXA is renally excreted and accumulates in renal failure, requiring dose reduction even for topical use if significant systemic absorption occurs, as noted in the Journal of Hepatology and Critical Care journal 3, 4, 5

The American College of Chest Physicians recommends applying 5 mL of tranexamic acid (500 mg) directly to the bleeding gum using gauze or cotton swabs soaked in the solution, 3-4 times a day for 1-2 days, for patients with gingivorragia, especially those who are anticoagulated 6
For patients undergoing dental procedures, administer 5-10 minutes before the procedure, and continue topical applications 3-4 times a day for 1-2 days after the procedure 6
In patients receiving oral anticoagulants (warfarin), continue anticoagulation without interruption and coadminister topical tranexamic acid, maintaining a clinically relevant bleeding risk of less than 5% and a thromboembolic risk of less than 0.1% 6

The Hepatology society notes that tranexamic acid is excreted through the kidneys and accumulates in renal insufficiency, requiring dose adjustment even for topical use if significant systemic absorption occurs 7

The Chest society reports that over 8,000 patients who received lysine analogs like tranexamic acid showed no increased risk of arterial or venous thrombotic events, confirming a favorable safety profile 6